...
首页> 外文期刊>Chemistry & biology >Engineering of a minimal modular polyketide synthase, and targeted alteration of the stereospecificity of polyketide chain extension
【24h】

Engineering of a minimal modular polyketide synthase, and targeted alteration of the stereospecificity of polyketide chain extension

机译:最小化模块化聚酮化合物合酶的工程设计,并靶向改变聚酮化合物扩链的立体特异性

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Polyketides are a large and structurally diverse group of natural products that include antibiotics, antifungal agents and immunosuppressant compounds. Polyketides are biosynthesised in filamentous bacteria on modular polyketide synthases (PKSs) in which each cycle of chain extension requires a different 'module' of enzymatic activities. The recently proposed dimeric model for modular PKSs predicts that even a single-module PKS should be catalytically active in the absence of other PKS components, Researchers are also interested in manipulating the stereochemical outcome of polyketide chain extension using genetic engineering of domains within each module. Results: We have constructed a minimal modular PKS from the erythromycin-producing PKS (DEBS) of Saccharopolyspora erythraea. The diketide synthase (DKS1-2) consists of a single chimaeric extension module, derived from the DEBS module 1 ketoacyl-ACP synthase (KS), sandwiched between a loading module and a chain-terminating thioesterase. When DKS1-2 was expressed in S. erythraea, the strain preferentially accumulated the diketide (2R,3S)-2-methyl-3-hydroxy pentanoic acid. Conclusions: These results demonstrate that, as predicted, even a single-module PKS is catalytically active in the absence of other DEBS proteins. In its normal context, the ketosynthase domain KS1 is thought to generate a (2S)-2-methyl-3-hydroxy intermediate by epimerising the initial product of carbon-carbon chain formation, the (2R)-2-methyl-3-ketoester. The observed formation of the alternative (2R)-2-methyl-3-hydroxy product catalysed by DKS1-2 provides strong support for this proposal, and indicates how targeted alteration of stereospecificity can be achieved on a modular PKS. [References: 35]
机译:背景:聚酮化合物是一大类结构多样的天然产物,包括抗生素,抗真菌剂和免疫抑制剂化合物。聚酮化合物是在模块化聚酮化合物合酶(PKS)上的丝状细菌中生物合成的,其中链延长的每个循环都需要不同的酶活性“模块”。最近提出的模块化PKS的二聚体模型预测,即使在没有其他PKS组分的情况下,即使是单模块PKS也应具有催化活性。研究人员也对使用每个模块内结构域的遗传工程来操纵聚酮化合物扩链的立体化学结果感兴趣。结果:我们已经从产红霉素的糖多孢菌的PKS(DEBS)中构建了一个最小的模块化PKS。双酮化合物合酶(DKS1-2)由一个衍生自DEBS模块1的酮酰基ACP合酶(KS)的嵌合扩展模块组成,夹在加载模块和链终止硫酯酶之间。当DKS1-2在红霉菌中表达时,该菌株优先积聚二酮化合物(2R,3S)-2-甲基-3-羟基戊酸。结论:这些结果表明,正如所预测的,即使在没有其他DEBS蛋白的情况下,即使是单模块PKS也具有催化活性。在其正常情况下,酮合酶结构域KS1被认为通过差向异构化碳-碳链形成的初始产物(2R)-2-甲基-3-酮酸酯而生成(2S)-2-甲基-3-羟基中间体。观察到的由DKS1-2催化的(2R)-2-甲基-3-羟基替代产物的形成为该提议提供了有力的支持,并表明如何在模块化PKS上实现靶向的立体特异性改变。 [参考:35]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号